At Advanced Therapies Week, OmniaBio CEO Mitchel Sivilotti shared how the company is redefining manufacturing in the cell and gene therapy sector with the opening of its new commercial CDMO facility in Hamilton, Canada. Speaking with Benjamin McLeod of Convey Bio, Mitchel Sivilotti detailed how OmniaBio is addressing one of the industry’s biggest challenges: reducing the cost of advanced therapies to make them more accessible to patients worldwide.
The newly designed facility was purpose-built for high-throughput manufacturing, incorporating advanced robotics, integrated data systems, and process automation. These technologies are being combined with process analytical technology (PAT) to create transparency and efficiency in manufacturing workflows. By capturing and analyzing data in real time, OmniaBio aims to provide clients with higher quality, more consistent products while offering greater visibility into their manufacturing processes.
Beyond automation, the facility is designed with logistics, material movement, and scalability in mind, supporting platforms such as induced pluripotent stem cells (iPSCs), allogeneic cell therapies, and lentiviral vector production.
Mitchel Sivilotti also discussed the importance of collaboration in driving innovation. As a spinout of CCRM, OmniaBio maintains strong ties with R&D partners like Cytiva, along with support from Canadian federal programs and organizations like Invest Ontario and Next Generation Manufacturing Canada (NGen).
With two pivotal client programs already underway, OmniaBio's facility launch marks a significant step forward in advancing commercialization pathways for advanced therapies. The company's focus on optimizing timelines, reducing production costs, and improving product quality positions it as a key player in the evolving CDMO landscape.
Watch the full interview on AT-TV to explore how OmniaBio is setting new standards in advanced therapies manufacturing.
)